Decline in sales of Alz, a joint-function improvement drug
First written in FY2019-Q1. 17 of 25 entries say "Restated". Latest entry: 2026-11-09.
Kaken Pharmaceutical moved to the "Worse" side of this theme in 2025.
0 other companies' latest entry also says "Restated".
- FY2026WorsenedAnnual report
「Revenue ultimately declined due to the progress made in switching Krenafin to its AG version and other factors.」
For Alz, which had been cited as contributing to higher sales through the previous fiscal year, a decline in sales due to drug price revisions and other factors was explicitly stated in the current fiscal year, making it a factor behind lower pharmaceutical-business revenue. - FY2026-H1WorsenedAnnual report
「Revenue declined because sales of Alz, a joint-function improvement drug, generic drugs excluding Krenafin AG, and other products decreased due to the impact of drug price revisions and other factors.」
For Alz, which had been cited as contributing to higher sales through the previous fiscal year, a decline in sales due to the impact of drug price revisions and other factors was again explicitly stated. - FY2025-H1SoftenedAnnual report
「Growth in Alz, a joint-function improvement drug, following the discontinuation of a competing product」
For Alz, which had been cited as a factor behind declining sales through the previous fiscal year, growth in sales following the discontinuation of a competing product was reported, weakening the theme of declining sales. - FY2024-Q3RestatedAnnual report
「In pharmaceuticals and medical devices, sales of Alz, a joint-function improvement drug, Ekurock, a treatment for primary axillary hyperhidrosis, and other products increased, while」
The increase in Alz sales continues to be cited, together with Ekurock and other products, as a contributor to higher pharmaceutical-business revenue, and the theme of declining sales remains weak. - FY2024-Q2RestatedAnnual report
「While sales of Ekurock, a treatment for primary axillary hyperhidrosis, Alz, a joint-function improvement drug, and other products increased,」
The increase in Alz sales continues to be cited, together with Ekurock and other products, as a contributor to higher pharmaceutical-business revenue, and the theme of declining sales remains weak. - FY2024-Q1SoftenedAnnual report
「Sales increased for the primary axillary hyperhidrosis treatment Ecloc, for which a new Twist Bottle container was launched on 1 June, and the joint-function-improving agent Alz, among others. However, sales declined for the absorbable adhesion barrier Seprafilm and the onychomycosis treatment Crenafin, among others, due to the impact of competing products and drug price revisions, resulting in lower revenue.」
For Alz, whose sales had been described as declining in the previous fiscal year and through the previous quarter, an increase in sales was explicitly stated for the current quarter, together with Ekurock and other products. - FY2023-Q3RestatedAnnual report
「Pharmaceutical and medical device sales declined because of lower sales of the joint-function improvement agent アルツ, the absorbable adhesion barrier セプラフィルム and other products.」
The decline in Alz sales continues to be cited, together with Seprafilm and other products, as a factor behind lower pharmaceutical-business revenue. - FY2023-Q2RestatedAnnual report
「Pharmaceutical and medical device sales declined because of lower sales of the joint-function improvement agent アルツ, the absorbable adhesion barrier セプラフィルム and other products.」
The decline in Alz sales continues to be cited, together with Seprafilm and other products, as a factor behind lower pharmaceutical-business revenue. - FY2023-Q1RestatedAnnual report
「Pharmaceutical and medical device sales declined because of lower sales of the onychomycosis treatment クレナフィン, the joint-function improvement agent アルツ and other products.」
The decline in Alz sales continues to be cited, together with Krenafin and other products, as a factor behind lower pharmaceutical-business revenue. The impact of drug price revisions and other factors was identified as the background. - FY2022-Q3RestatedAnnual report
「Although sales of Krenafin, a treatment for toenail onychomycosis, declined, revenue increased due to higher sales of Ekurock, a treatment for primary axillary hyperhidrosis, Alz, a joint-function improvement drug, and generic drugs, among other factors.」
The increase in Alz sales was cited again following the cumulative second quarter of the previous fiscal year, and the theme of declining Alz sales remains weak. - FY2022-Q2RestatedAnnual report
「For pharmaceuticals and medical devices, sales of the onychomycosis treatment クレナフィン declined, but sales increased because of higher sales of the joint-function improvement agent アルツ, generic drugs and other products.」
The increase in Alz sales was cited again following the previous first quarter, and the theme of declining Alz sales remains weak. - FY2022-Q1SoftenedAnnual report
「For pharmaceuticals and medical devices, sales of the onychomycosis treatment クレナフィン were broadly unchanged year on year, but sales increased because of higher sales of the joint-function improvement agent アルツ and other products.」
For Alz, whose sales had been described as declining in the previous fiscal year and through the previous first quarter, an increase in sales was explicitly stated for the current first quarter. - FY2021RestatedAnnual report
「In pharmaceuticals and medical devices, revenue declined due to lower sales of ARTZ, a joint function improvement agent, and KLEENAFIN, a treatment for onychomycosis, as well as lower overseas sales.」
The decline in Alz sales was cited as a factor behind lower pharmaceutical-business revenue for the fiscal year, together with declines in Krenafin sales and overseas revenue. - FY2021-Q3RestatedAnnual report
「Pharmaceutical and medical device sales declined because of lower sales of the joint-function improvement agent アルツ and the onychomycosis treatment クレナフィン, among other factors.」
The decline in Alz sales continues to be cited from the previous quarter, together with the decline in Krenafin sales, as a factor behind lower pharmaceutical-business revenue. - FY2021-Q2RestatedAnnual report
「Pharmaceutical and medical device sales declined because of lower sales of the joint-function improvement agent アルツ and the onychomycosis treatment クレナフィン, among other factors.」
The decline in Alz sales continues to be cited, together with the decline in Krenafin sales, as a factor behind lower pharmaceutical-business revenue. - FY2021-Q1RestatedAnnual report
「Pharmaceutical and medical device sales declined because of lower sales of the joint-function improvement agent アルツ and the onychomycosis treatment クレナフィン, among other factors.」
The decline in Alz sales is cited, together with the decline in Krenafin sales, as a factor behind lower pharmaceutical-business revenue. - FY2020-Q3RestatedAnnual report
「In pharmaceuticals and medical devices, sales of Krenafin, a treatment for toenail onychomycosis, and Seprafilm, an absorbable adhesion barrier, were broadly in line with the previous year, but revenue declined due to lower sales of Alz, a joint-function improvement drug, and Lipidil, a treatment for hyperlipidemia, among other factors.」
The decline in Alz sales continues to be cited as a factor behind lower pharmaceutical-business revenue that could not be offset by sales of Krenafin and other products. - FY2020-Q2RestatedAnnual report
「For pharmaceuticals and medical devices, sales of the onychomycosis treatment クレナフィン, the joint-function improvement agent アルツ and the absorbable adhesion barrier セプラフィルム were broadly unchanged year on year, but」
Alz sales, which had been described as declining through the previous fiscal year and as a factor behind lower revenue through the previous quarter, were described as being at approximately the previous year's level in the current cumulative second quarter. - FY2020-Q1SoftenedAnnual report
「Sales of the onychomycosis treatment クレナフィン and the joint-function improvement agent アルツ were broadly unchanged year on year, but」
While Alz sales had been cited as a factor behind lower pharmaceutical-business revenue through the previous fiscal year, sales were described as being at approximately the previous year's level in the current first quarter, weakening the wording around the decline. - FY2019RestatedAnnual report
「Revenue declined due to lower sales of Alz, a joint-function improvement drug, and Lipidil, a treatment for hyperlipidemia, among other factors.」
The decline in Alz sales was cited for the fiscal year as a factor behind lower pharmaceutical-business revenue that could not be offset by higher Krenafin sales. - FY2019-Q3RestatedAnnual report
「Sales of Crenafin, a treatment for onychomycosis, increased, but sales declined due to lower sales of Alz, a joint-function improvement agent, and Lipidil, a treatment for hyperlipidemia, among other factors.」
The decline in Alz sales continues to be cited as a factor behind lower pharmaceutical-business revenue that could not be offset by higher Krenafin sales. - FY2019-Q2RestatedAnnual report
「Sales of Crenafin, a treatment for onychomycosis, increased, but sales declined due to lower sales of Alz, a joint-function improvement agent, and Lipidil, a treatment for hyperlipidemia, among other factors.」
The decline in Alz sales continues to be cited as a factor behind lower pharmaceutical-business revenue that could not be offset by higher Krenafin sales. - FY2019-Q1First statedAnnual report
「Sales declined, mainly due to lower sales of Alz, a joint-function improvement agent, and Seprafilm, an absorbable adhesion-prevention barrier.」
The decline in Alz sales was explicitly identified, together with the decline in Seprafilm sales, as a factor behind lower revenue in the pharmaceutical business.